News

In relapsing-remitting multiple sclerosis patients who switched from placebo to laquinimod, 52% reduction in the mean number of GdE lesions was observed (p

This Phase IIb spasticity trial is evaluating the safety, tolerability and efficacy of AV650 in multiple sclerosis (MS) patients at doses up to 900mg/day for one month followed

According to the company, the FDA has not requested any new clinical studies surrounding the efficacy or safety of Actemra as a prerequisite for approval. The FDA has

Under the agreement, the companies will co-develop Maxy-4 candidates for rheumatoid arthritis and other autoimmune diseases and Astellas will exclusively develop Maxy-4 candidates for transplant rejection. In addition,

The 510(k) clearance was based on the results of a multi-center, international clinical trial that established equivalency of titanium:sapphire laser trabeculoplasty (TLT) to argon laser trabeculoplasty (ALT) in

According to the company, MultiBead assays do not require specialized instrumentation and work on commercially available dual-laser flow cytometers, making access to instrumentation convenient and economical. Proprietary data

Dr Ohrstrom was previously part of the senior management team that took ZymoGenetics public, and played a key role in bringing recombinant human thrombin to the US market.

Based on the original Prescription Drug User Fee Act (PDUFA) date for Zolpimist, the FDA will reply on or before December 19, 2008. NovaDel submitted its Zolpimist application

Mr Harwood is a healthcare industry advisor for Avista Capital Partners, a private equity firm. Prior to working with Avista, Mr Harwood was president and CEO of privately-held